|

The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination

RECRUITINGSponsored by University of Athens
Actively Recruiting
SponsorUniversity of Athens
Started2017-11-03
Est. completion2026-12-31
Eligibility
Age45 Years – 80 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT03878706

Summary

A. Four groups of patients with type 2 diabetes mellitus with high or very high cardiovascular risk or heart failure with preserved ejection fraction (HFpEF) will be studied before and at 6 and 12 months of treatment: * 60 patients treated with a combination of GLP1 analogue and SGLT2 inhibitor ± metformin * 60 patients treated with GLP-1 agonist as a second step after metformin * 60 patients treated with SGLT2 inhibitor as a second step after metformin * 60 patients treated with a combination of insulin and other antidiabetic agents (metformin - DPP4 inhibitors) Individuals will be equal distributed as far as age, gender and body mass index concerned. In addition, patients suffered from kidney disease and retinopathy are excluded.

Eligibility

Age: 45 Years – 80 YearsHealthy volunteers accepted
Inclusion Criteria:

* Subject has type 2 diabetes mellitus
* Subject has high or very high cardiovascular risk
* Subject has heart failure with preserved ejection fraction

Exclusion Criteria:

* Subject has type 1 diabetes mellitus
* Subject has kidney disease
* Subject has retinopathy

Conditions2

DiabetesDiabetes Mellitus, Type 2

Browse More Trials

Diabetes trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.